BridgeBio Pharma, Inc. 13D

Opportunities Fund has been reducing its position through open-market sales with no stated activist intentions.

The Schedule 13D exhibit shows that Opportunities Fund, a reporting person, has recently been selling shares of the issuer’s common stock in the open market in a series of transactions between May 22, 2026 and July 9, 2026 at prices ranging from approximately $66 to $90 per share, indicating a reduction in its position rather than an accumulation or explicitly activist move; the filing does not disclose the remaining stake size or any specific intentions beyond ordinary portfolio management sales.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

13D

Source Type

fda

Accession

0000905148-26-003237

Alert Tier

7